Just for CHM 1101 alone, the GBM CLTX CAR-T, the MC should be at least USD 100m / AUD 150m, about 20c.
Plus the CD17 CAR-T, the world's first attacking solid cancer on its own, the next big thing after the CD19 CAR-T which so far only attacks liquid cancers such as blood and skin. Brought to us by the ones who developed the CD19 CAR-Ts.
And all that valued less than AUD 10m!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
GLTA
Ann: Half Yearly Report and Accounts, page-14
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
